New Research Into Cognitive Impairment Associated With Schizophrenia (CIAS) Market-Pipeline Review, H1 2016

Summary

 

Global Markets Direct’s, ‘Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline Review, H1 2016’, provides an overview of the Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/143787

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Cognitive Impairment Associated With Schizophrenia (CIAS)

– The report reviews pipeline therapeutics for Cognitive Impairment Associated With Schizophrenia (CIAS) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Cognitive Impairment Associated With Schizophrenia (CIAS) therapeutics and enlists all their major and minor projects

– The report assesses Cognitive Impairment Associated With Schizophrenia (CIAS) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Cognitive Impairment Associated With Schizophrenia (CIAS)

Purchase a copy of Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline Review, H1 2016 visit @ http://www.orbisresearch.com/contact/purchase/143787

Reasons to buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

– Identify and understand important and diverse types of therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS)

– Identify potential new clients or partners in the target demographic

– Develop strategic initiatives by understanding the focus areas of leading companies

– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

– Devise corrective measures for pipeline projects by understanding Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline depth and focus of Indication therapeutics

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned:

Addex Therapeutics Ltd

Aequus Pharmaceuticals Inc.

AgeneBio Inc.

APeT Holding BV

Berg LLC

BioCrea GmbH

BrainStorm Cell Therapeutics Inc.

Cellceutix Corporation

Confluence Pharmaceuticals LLC

Curemark, LLC

Domain Therapeutics SA

  1. Hoffmann-La Roche Ltd.

Heptares Therapeutics Limited

Intra-Cellular Therapies, Inc.

Luc Therapeutics, Inc.

MedDay

Omeros Corporation

Otsuka Holdings Co., Ltd.

Retrophin Inc.

Sage Therapeutics, Inc.

Saniona AB

Sumitomo Dainippon Pharma Co., Ltd.

Some Points Form TOC:

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Cognitive Impairment Associated With Schizophrenia (CIAS) Overview 10

Therapeutics Development 11

Pipeline Products for Cognitive Impairment Associated With Schizophrenia (CIAS) – Overview 11

Cognitive Impairment Associated With Schizophrenia (CIAS) – Therapeutics under Development by Companies 12

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Cognitive Impairment Associated With Schizophrenia (CIAS) – Products under Development by Companies 17

Cognitive Impairment Associated With Schizophrenia (CIAS) – Companies Involved in Therapeutics Development 19

AbbVie Inc. 19

Amarantus Bioscience Holdings, Inc. 20

For any enquires before buying, connect with us @ enquiry@orbisresearch.com

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

 

Contact Information:

Hector Costello

Senior Manager – Client Engagements

4144N Central Expressway,

Suite 600, Dallas,

Texas – 75204, U.S.A.

Phone No.: +1 (214) 884-6817; +9164101019

Follow Us on LinkedIn: https://www.linkedin.com/company/orbis-research

Follow us on Twitter: https://twitter.com/orbisresearch

Like us on Facebook: https://www.facebook.com/OrbisResearch

 

Leave a Reply

Designed by CyFocus.com
Powered by CyFocus.net